Regina Hensley, APRN
Psychiatric/Mental Health · Columbia, SCNPI 1548325640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,327, more than ten times the $24 reported in 2022.
Across 203 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$815
- Teva Pharmaceuticals USA, Inc.$609
- Johnson & Johnson$585
- Otsuka America Pharmaceutical, Inc.$482
- Alkermes, Inc.$478
- AbbVie$235
- plus $251 from 6 others
What the payments were for
- Food & beverage$3,16091%
- Education$2969%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 54 | $815 |
| Teva Pharmaceuticals USA, Inc. | 35 | $609 |
| Johnson & Johnson | 22 | $585 |
| Otsuka America Pharmaceutical, Inc. | 31 | $482 |
| Alkermes, Inc. | 27 | $478 |
| AbbVie | 23 | $235 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $21 |
| Indivior Inc. | 1 | $18 |
How this compares
$3,455 in reported general payments places this provider in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 51 | $127,521 |
| VraylarCariprazine Hcl | 17 | $25,204 |
| Abilify MaintenaAripiprazole | 11 | $24,233 |
| Fluphenazine Decanoate | 23 | $3,291 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $2,784 |
| Fluphenazine Hcl | 28 | $2,517 |
| Aripiprazole | 46 | $2,127 |
| Haloperidol Decanoate | 22 | $1,105 |
| Benztropine Mesylate | 63 | $935 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $802 |
| Olanzapine | 44 | $790 |
| Quetiapine Fumarate | 59 | $743 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $732 |
| Hydroxyzine Pamoate | 44 | $711 |
| Ziprasidone Hcl | 19 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $585 | $127,52151 claims |
| AbbVieVraylar | $235 | $25,20417 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $482 | $24,23311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Columbia
- Elizabeth EggebrechtColumbia$11K
- Natalie VerenesColumbia$10K
- April HuttoColumbia$6K
- Penny LoyaColumbia$5K
- Milissa DavisColumbia$5K
- Cheryl SuberColumbia$4K
- Henretta MiltonColumbia$4K
- Jennipher Immanuel ManoharColumbia$4K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.